Effects of edaravone within 4.5h acute ischaemic stroke on frequency of symptomatic intracranial haemorrhage in patients receiving recombinant tissue-plasminogen activator (rt-PA)

Trial Profile

Effects of edaravone within 4.5h acute ischaemic stroke on frequency of symptomatic intracranial haemorrhage in patients receiving recombinant tissue-plasminogen activator (rt-PA)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2015

At a glance

  • Drugs Edaravone (Primary) ; Alteplase
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms PROTECT4.5
  • Most Recent Events

    • 14 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top